See the DrugPatentWatch profile for Prolia
What is the risk of osteonecrosis of the jaw (ONJ) with Prolia?
Prolia (denosumab) can cause osteonecrosis of the jaw (ONJ), though it is uncommon. The risk is higher in people who already have risk factors such as invasive dental procedures, poor oral health, cancer, or long-term antiresorptive treatment. The exact incidence depends on the population studied (osteoporosis vs cancer regimens) and treatment duration.
How does the ONJ risk compare in osteoporosis vs cancer treatment?
ONJ risk tends to be higher in cancer settings, where denosumab is often used at higher doses and in combination with other factors that raise ONJ risk (for example, chemotherapy, advanced cancer, and more frequent dental procedures). In osteoporosis dosing, ONJ is lower but still present.
What increases the risk most?
Common risk factors linked to ONJ include:
- Recent or planned invasive dental work (tooth extraction, implants, major gum surgery)
- Poor oral hygiene or existing dental disease (periodontitis, ill-fitting dentures)
- Coexisting cancer (and cancer treatments that affect healing)
- Treatment duration with antiresorptives (the longer the exposure, the higher the cumulative risk)
- Steroids, smoking, diabetes, and other conditions that impair healing
If you have multiple risk factors, your clinicians typically treat you as higher risk and manage dental care more carefully.
Does ONJ show up quickly, or after long-term Prolia use?
ONJ can occur at any time, but risk generally increases with longer exposure to antiresorptive therapy. This is why dental evaluation before starting therapy and ongoing preventive dental care matter.
What should patients do to reduce risk before and during Prolia?
Clinicians commonly recommend:
- Have a dental exam and address any needed invasive dental problems before starting Prolia.
- Maintain good oral hygiene and regular dental follow-up.
- Tell your dentist and prescribing clinician that you take Prolia before any dental procedure.
- Promptly report symptoms such as jaw pain, swelling, loose teeth, exposed bone, or nonhealing sores.
For planned extractions or implants, clinicians may coordinate timing with Prolia dosing to reduce the chance of ONJ, but the approach varies by patient risk.
What symptoms mean you should seek care urgently?
Seek prompt evaluation if you develop:
- Pain or swelling in the jaw
- Exposed bone in the mouth or persistent nonhealing sores
- Loose teeth without obvious cause
- Numbness or tingling in the jaw area
- Symptoms that do not improve after dental treatment
Early evaluation can affect outcomes.
Is ONJ permanent, and how is it treated?
ONJ management usually focuses on stopping progression and controlling infection or inflammation (for example, oral rinses/antimicrobial care, conservative dental management, and pain control). Some cases improve, but healing can take time; severe cases may require specialist care. The key is early recognition and care by clinicians experienced in ONJ.
What’s the difference between “osteonecrosis of the jaw” and other bone issues?
ONJ specifically refers to jaw bone that becomes exposed and fails to heal within a defined period. It is different from other rare bone or musculoskeletal adverse effects, and it has distinct prevention and dental-care considerations.
Can you switch off Prolia if you’re worried about ONJ?
Stopping Prolia can be considered in some situations, but it must be done with medical guidance. Denosumab discontinuation can increase the risk of rebound vertebral fractures, so clinicians often plan a transition to another osteoporosis medication if Prolia is stopped.
If you’re searching because you want numbers: what you should look for
ONJ incidence is reported differently across studies (osteoporosis vs cancer regimens, duration, and diagnostic criteria). If you share your context—osteoporosis or cancer dosing, how long you’ve been on Prolia, and whether you’ve had dental extractions/implants—I can help interpret what the reported risk figures likely mean for your situation.
---
Sources
I can’t cite specific ONJ incidence rates or study figures because no source text was provided in your prompt. If you paste the guideline/article excerpt you’re using (or tell me the exact Prolia label or study), I’ll extract the reported ONJ risk and present it with precise numbers and citations.